Adarx Pharmaceuticals
ADRX
17.33
-1.25
-6.73%
Adarx Pharmaceuticals
US · ADRX
#2823 by market cap
Listed 2026
17.33
-1.25
-6.73%
Live - 5344 symbols - heartbeat 524s ago
· 2026-10-08 08:27
Pre-market
17.67
+1.96%
After-hours
17.22
-0.63%
Overnight
17.04
-1.67%
- Market cap
- 1.77B
- P/E (TTM)i
- -20.15
- P/Bi
- -7.06
- EPSi
- -0.97
- Div yieldi
- 0.00%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on ADRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.41, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 2 years
Margins
- Operating margin
- -2,562.05%
- Net margin
- -2,119.11%
Key ratios & quality
- Altman Z-Scorei
- 1.41
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2024 | 2025 |
|---|---|---|
| Revenue | 0 | 3.45M |
| Gross profit | -- | -- |
| Selling & admin expenses | 14.88M | 20.30M |
| Research & development | 43.36M | 71.51M |
| Operating profit | -58.23M | -88.37M |
| Pretax profit | -46.36M | -73.09M |
| Tax | -- | -- |
| Net profit | -46.36M | -73.09M |
| Basic EPS | -1 | -1 |
| Diluted EPS | -0.62 | -0.97 |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Revenue | 0 | 208.00K | 2.14M | 746.00K |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 5.00M | 4.26M | 5.62M | 5.90M |
| Research & development | 12.89M | 17.07M | 23.58M | 24.74M |
| Operating profit | -17.89M | -21.12M | -27.06M | -29.89M |
| Pretax profit | -15.55M | -18.09M | -22.67M | -25.76M |
| Tax | -- | -- | -- | -- |
| Net profit | -15.55M | -18.09M | -22.67M | -25.76M |
| Basic EPS | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.21 | -0.24 | -0.22 | -0.25 |
Balance sheet
| Line item | 2024 | 2025 |
|---|---|---|
| Total current assets | 225.67M | 493.38M |
| Cash & ST investments | 219.48M | 480.00M |
| Inventory | -- | -- |
| Total assets | 233.45M | 507.66M |
| Total current liabilities | 8.94M | 30.49M |
| Short-term debt | 794.00K | 1.71M |
| Long-term debt | -- | -- |
| Total liabilities | 370,599,000.00 | 709,910,000.00 |
| Total equity | -137.15M | -202.26M |
| Retained earnings | -147.61M | -220.70M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Total current assets | -- | -- | 468.72M | 441.54M |
| Cash & ST investments | -- | -- | 455.82M | 427.25M |
| Inventory | -- | -- | -- | -- |
| Total assets | -- | -- | 482.56M | 456.33M |
| Total current liabilities | -- | -- | 29.76M | 34.01M |
| Short-term debt | -- | -- | 1.71M | 1.71M |
| Long-term debt | -- | -- | -- | -- |
| Total liabilities | -- | -- | 708,290,000.00 | 707,384,000.00 |
| Total equity | -- | -- | -225.73M | -251.05M |
| Retained earnings | -- | -- | -243.37M | -269.13M |
Cash flow
| Line item | 2024 | 2025 |
|---|---|---|
| Operating cash flow | -48.56M | 262.29M |
| Depreciation & amortization | 1.50M | 2.33M |
| Free cash flow | -49.02M | 259.35M |
| Dividends paid | -- | -- |
| Stock buybacks / issuance | -- | -- |
| Ending cash balance | 14.03M | 66.52M |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| Operating cash flow | -12.71M | 313.44M | -22.68M | -27.19M |
| Depreciation & amortization | 514.00K | 626.00K | 720.00K | 735.00K |
| Free cash flow | -13.20M | 312.45M | -22.76M | -27.56M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- |
| Ending cash balance | 15.27M | 65.65M | 63.86M | 58.48M |
Returns & efficiency
| Line item | 2024 | 2025 |
|---|---|---|
| ROE %i | -- | -- |
| ROA %i | -19.86 | -19.72 |
| ROIC %i | -- | -- |
| 5-year avg ROE %i | -- | -- |
| EBIT margin %i | -- | -2,562.05 |
| FCF / sales %i | -- | 7,519.66 |
| Current ratioi | 25.25 | 16.18 |
| Quick ratioi | 24.56 | 15.75 |
| Debt / assetsi | 1.85 | 1.52 |
| LT debt / equityi | -- | -- |
| Interest coveragei | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- |
| Net income CAGR (3Y) %i | -- | -- |
| FCF CAGR (3Y) %i | -- | -- |
| Line item | 2025-03 | 2025-06 | 2026-03 | 2026-06 |
|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- |
| ROA %i | -- | -- | -16.62 | -19.26 |
| ROIC %i | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -1,745.09 | -1,734.98 |
| FCF / sales %i | -- | -- | 4,469.46 | -- |
| Current ratioi | -- | -- | 15.75 | 12.98 |
| Quick ratioi | -- | -- | 15.32 | 12.56 |
| Debt / assetsi | -- | -- | 1.52 | 1.51 |
| LT debt / equityi | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing proprietary RNA targeting delivery platforms as well as technologies for silencing or100.00%
Quote time 2026-10-08 08:27:44 · For reference only, not investment advice and not tailored to your situation.